Bosutinib
Back to searchMolecule Structure
Scientific Name
Bosutinib
Description of the Drug
Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06616
http://www.drugbank.ca/drugs/DB06616
Brand Name(s)
Bosulif
Company Owner(s)
Pf Prism Cv
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase ABL | SINGLE PROTEIN | INHIBITOR | CHEMBL1862 |
| Bcr/Abl fusion protein | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2096618 |
| Tyrosine-protein kinase Lyn | SINGLE PROTEIN | INHIBITOR | CHEMBL3905 |
| Tyrosine-protein kinase SRC | SINGLE PROTEIN | INHIBITOR | CHEMBL267 |
| Tyrosine-protein kinase HCK | SINGLE PROTEIN | INHIBITOR | CHEMBL3234 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL158390 | ||
| Human Metabolome Database | HMDB0240205 | ||
| DrugBank | DB06616 | ||
| PubChem: Thomson Pharma | 14885411 | ||
| PubChem | 5328940 | ||
| LINCS | LSM-1190 | ||
| Nikkaji | J1.678.415J | ||
| PDBe | DB8 | ||
| BindingDB | 4552 | ||
| DrugCentral | 4359 | ||
| Brenda | 18227 | 213596 | 14073 |
| ChemicalBook | CB22673646 | ||
| Guide to Pharmacology | 5710 | ||
| rxnorm | BOSUTINIB MONOHYDRATE | BOSULIF | BOSUTINIB |
| PubChem: Drugs of the Future | 26746630 | ||
| ChEBI | 39112 | ||
| ZINC | ZINC000022448983 |
